180 Life Sciences Corp - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ATNF Nasdaq 2834 https://180lifesciences.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for 180 Life Sciences Corp

180 Life Sciences Announces Presentation at the Gordon Conference - Feb 27th, 2023 1:30 pm
180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren’s Disease Treatment and Application - Feb 23rd, 2023 12:30 pm
180 Life Sciences Provides Update Regarding Anti-TNF Frozen Shoulder Trial - Feb 22nd, 2023 9:30 pm
180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren’s Disease - Jan 25th, 2023 1:45 pm
180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom - Jan 17th, 2023 1:00 pm
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement - Jan 5th, 2023 1:30 pm
180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s Disease - Jan 4th, 2023 1:30 pm
180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders - Dec 29th, 2022 1:30 pm
180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Dec 23rd, 2022 1:00 pm
180 Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Dec 20th, 2022 7:11 pm
180 Life Sciences Corp. Announces 1-for 20 Reverse Stock Split as Part of Nasdaq Compliance Plan - Dec 16th, 2022 2:00 pm
180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren’s Contracture - Nov 30th, 2022 10:00 pm
180 Life Sciences to Participate in A.G.P.’s Virtual Biotech Conference to be Held November 30 – December 1, 2022 - Nov 21st, 2022 1:30 pm
CORRECTION: Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease - Nov 15th, 2022 5:37 pm
Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease - Nov 15th, 2022 1:00 pm
180 Life Sciences Issues Letter to Stockholders - Sep 26th, 2022 12:30 pm
180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen Shoulder - Aug 22nd, 2022 12:30 pm
180 Life Sciences Announces That the University of Oxford Has Been Awarded a Grant From the National Institute for Health and Care Research in the U.K. to Conduct a Clinical Trial in Post Operative Delirium/Cognitive Deficit in a Jointly Funded Program With 180 Life Sciences Corp. - Jul 27th, 2022 12:30 pm
180 Life Sciences Corp. Announces Closing of $6.5 Million Registered Direct Offering - Jul 21st, 2022 12:00 pm
180 Life Sciences Corp. Announces $6.5 Million Registered Direct Offering - Jul 18th, 2022 12:30 pm